Journal article

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Sarah P Blagden, Anne L Hamilton, Linda Mileshkin, Shirley Wong, Agnieszka Michael, Marcia Hall, Jeffrey C Goh, Alla S Lisyanskaya, Michelle DeSilvio, Eleni Frangou, Euan A Stronach, Prashanth Gopalakrishna, Tarek M Meniawy, Hani Gabra

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2019

Grants

Funding Acknowledgements

Y The study was designed by the lead investigators and the sponsor (GlaxoSmithKline; afuresertib subsequently became an asset of Novartis Pharma AG). The sponsor collected and analyzed the data in conjunction with the authors. Early versions of this manuscript were supported by Matthew Naylor and funded by Novartis Pharmaceuticals Corporation. This work was also supported by the BRC, ECMC, and CRUK Clinical Centres, and the Ovarian Cancer Action Research Centre, Imperial College London.